Zacks' 7 Best Stocks for May, 2013
FREE Report for Zacks.com
Visitors Only

They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.

Today, you can see them free.

Close This Panel X

Are you a new Zacks Member or a visitor to Zacks.com?

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Stocks on the Move 05/17/2013

Company Name Symbol %Change
VIASAT INC VSAT
19.35%
OLD SECOND B OSBC
5.76%
GAMCO INVEST GBL
4.61%
CORNING INC GLW
4.47%
SYNCHRONOSS SNCR
4.23%

S&P Rates Aflac's Debentures

by Zacks Equity Research

September 20, 2012 | Comments : 0 Recommended this article: (0)

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Yesterday, Aflac Inc. ( AFL - Analyst Report ) had its junior subordinated debt rated by Standard & Poor's Ratings Services (S&P) at “BBB”, while the counterparty credit rating was denoted at “A-”. However, the outlook remains negative based on the negative sovereign rating in Japan.

Primarily, the rating agency assigned the “BBB” rating to Aflac’s recently issued long-term junior subordinated debentures worth $500 million. The debentures are slated to expire in 2052.The amount of the proceeds is expected to inject ample liquidity by utilizing funds for general corporate and capital purposes.

Following this debt issue, Aflac’s financial leverage is estimated to be about 25%, while fixed-charge coverage is projected to be within 20x, which aligns well with the company’s ratings, according to S&P. Meanwhile, in July 2012, ratings agency – A.M. Best Co. disclosed its rating of “a-” to the senior unsecured notes issued by Aflac, with a stable outlook. At that time, this rating agency had expected the company’s interest coverage to remain over 10x and financial leverage to stay below 25%.

Nevertheless, both the rating agencies have been backed by Aflac’s consistent growth of 3% in the U.S. in the first half of 2012, coupled with solid 51% growth in Japan, driven by vigorous bank channel and cancer product sales. Consequently, operating earnings climbed 3.4% for Aflac in the first half of 2012.

Further, the company’s National Association of Insurance Commissioners (NAIC) estimated risk-based capital ratio of 560 600% in the first half of 2012, improving from 493% in 2011, reflects its stable returns and appears impressive amid the ongoing de-risking program. Going ahead, the strong capital and surplus cash position is expected to mitigate this balance sheet risk and provide liquidity cushion to its long-term growth.

Overall, Aflac’s strong brand name and solid business model enabled it to improve earnings considerably faster than other life and health insurers such as Unum Group ( UNM - Analyst Report ) and Employer Holdings Inc. ( EIG - Snapshot Report ) .

Moreover, the company’s strong capital and surplus cash position is expected to mitigate balance-sheet risks and provide liquidity cushion in the long run, as well as return value to shareholders consistently. Hence, we continue to retain our long-term Neutral stance on the stock, with a Zacks Rank #3, implying a short-term Hold rating.

Email Print Share Rate Pos Rate Neg

Read/Post Comments (0) | Recommended this article (0)

Please login to Zacks.com or register to post a comment.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.